Marksans Pharma Ltd
NSE:MARKSANS

Watchlist Manager
Marksans Pharma Ltd Logo
Marksans Pharma Ltd
NSE:MARKSANS
Watchlist
Price: 205.7 INR 5.95%
Market Cap: 93.2B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one MARKSANS stock under the Base Case scenario is hidden INR. Compared to the current market price of 205.7 INR, Marksans Pharma Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MARKSANS Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.8
P/S
P/S
Price to Sales
3.8
vs History
12
vs Industry
30
Median 3Y
2.6
Median 5Y
1.9
Industry
2.3
Forward
3.5
More Details
25.3
P/E
P/E
Price to Earnings
25.3
vs History
12
vs Industry
16
Median 3Y
18.3
Median 5Y
12.5
Industry
19.8
Forward
24
More Details
42.9
P/OCF
P/OCF
Price to OCF
42.9
vs History
11
vs Industry
9
Median 3Y
22.1
Median 5Y
19.2
Industry
14.8
More Details
2 359
P/FCFE
P/FCFE
Price to FCFE
2 359
vs History
9
vs Industry
0
Median 3Y
32.8
Median 5Y
26.6
Industry
22.2
More Details
4.1
P/B
P/B
Price to Book Value
4.1
vs History
12
vs Industry
16
Median 3Y
2.9
Median 5Y
2.8
Industry
1.9
More Details
3.6
EV/S
EV/S
Enterprise Value to Sales
3.6
vs History
12
vs Industry
30
Median 3Y
2.3
Median 5Y
1.7
Industry
2.4
Forward
3.3
More Details
6.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.4
vs History
15
vs Industry
29
Median 3Y
4.6
Median 5Y
3.3
Industry
4.7
More Details
17.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.2
vs History
14
vs Industry
19
Median 3Y
12.1
Median 5Y
8
Industry
12
Forward
15.9
More Details
20.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
20.5
vs History
12
vs Industry
20
Median 3Y
14.1
Median 5Y
9.2
Industry
14.9
Forward
18.5
More Details
40.6
EV/OCF
EV/OCF
Enterprise Value to OCF
40.6
vs History
11
vs Industry
9
Median 3Y
19.5
Median 5Y
17.3
Industry
13.3
More Details
169.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
169.4
vs History
19
vs Industry
2
Median 3Y
48.9
Median 5Y
24.1
Industry
17.2
More Details
4.5
EV/IC
EV/IC
Enterprise Value to IC
4.5
vs History
15
vs Industry
15
Median 3Y
3.6
Median 5Y
2.8
Industry
1.7
More Details

Multiples Across Competitors

MARKSANS Competitors Multiples
Marksans Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Marksans Pharma Ltd
NSE:MARKSANS
93.2B INR 3.8 25.3 17.2 20.5
US
Eli Lilly and Co
NYSE:LLY
694B USD 15.4 65.5 38.2 42.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
365.2B USD 4.1 26 12.2 16
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.5 12.2 13.9
CH
Roche Holding AG
SIX:ROG
194.4B CHF 3.3 16.9 9.6 11.3
CH
Novartis AG
SIX:NOVN
174.3B CHF 4.1 17.9 10.8 13.9
UK
AstraZeneca PLC
LSE:AZN
155.2B GBP 3.8 28.9 125.6 191.8
US
Merck & Co Inc
NYSE:MRK
200.5B USD 3.1 11.7 8 9.4
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
FR
Sanofi SA
PAR:SAN
111.8B EUR 2.5 19.5 8.5 12.5
P/E Multiple
Earnings Growth PEG
IN
Marksans Pharma Ltd
NSE:MARKSANS
Average P/E: 25.6
25.3
26%
1
US
Eli Lilly and Co
NYSE:LLY
65.5
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.5
19%
1
CH
Roche Holding AG
SIX:ROG
16.9
16%
1.1
CH
Novartis AG
SIX:NOVN
17.9
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
19.5
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Marksans Pharma Ltd
NSE:MARKSANS
Average EV/EBITDA: 395.3
17.2
21%
0.8
US
Eli Lilly and Co
NYSE:LLY
38.2
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.2
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.6
7%
1.4
CH
Novartis AG
SIX:NOVN
10.8
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
125.6
9%
14
US
Merck & Co Inc
NYSE:MRK
8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
FR
Sanofi SA
PAR:SAN
8.5
6%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Marksans Pharma Ltd
NSE:MARKSANS
Average EV/EBIT: 1 698.6
20.5
26%
0.8
US
Eli Lilly and Co
NYSE:LLY
42.2
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
9%
1.3
CH
Novartis AG
SIX:NOVN
13.9
8%
1.7
UK
AstraZeneca PLC
LSE:AZN
191.8
21%
9.1
US
Merck & Co Inc
NYSE:MRK
9.4
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
12.5
14%
0.9

See Also

Summary
MARKSANS intrinsic value, competitors valuation, and company profile.
DCF Valuation
MARKSANS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MARKSANS stock valuation using valuation multiples.
Wall Street Estimates
MARKSANS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MARKSANS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 246,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.